Compare Caesars Entertainment Inc (CZR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs BIO-TECHNE Corp — how do they compare? Caesars Entertainment Inc trades at $29.52 (market cap $6.02B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and BIO-TECHNE Corp for 63 Days on average.
| CZR | TECH | |
|---|---|---|
Market Cap | $6.02B | $11.36B |
Volume | 6,412,151 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $72.61 |
52-Week Low | $18.14 | $43.31 |
Typical Hold Time | 31 Days | 63 Days |
Enterprise Value | $29.91B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.49, down 0.54% on the day, with a bearish technical signal and recent earnings misses. The company reported a net loss of $502M in 2025 despite $11.49B revenue, with negative ROE and ROA. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, while analyst consensus is mixed with a $30.75 price target.
The stock faces headwinds from consistent losses and high debt, but the merger offer provides a near-term catalyst. Risks include regulatory hurdles and competitive pressures, while institutional interest remains with HSBC increasing its stake. Upside is capped by weak profitability, but the acquisition premium offers potential stability.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
